{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:27:41Z","timestamp":1788982061137,"version":"build-2803163510"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Osteosarcoma (OS), the most common malignant tumor in the musculoskeletal system, mainly occurs in adolescents. OS results in high mortality and disability rates due to a fatal metastatic tendency and subsequent iatrogenic damage caused by surgery, radiotherapy and chemotherapy. Recently, immunotherapies have resulted in promising prognoses with reduced side effects compared with traditional therapies. Immune checkpoint inhibitors (ICIs), which are a representative immunotherapy for OS, enhance the antitumor effects of immune cells. ICIs have shown satisfactory outcomes in other kinds of malignant tumors, especially hemopoietic tumors. However, there is still a high percentage of failures or severe side effects associated with the use of ICIs to treat OS, leading to far worse outcomes. To reveal the underlying mechanisms of drug resistance and side effects, recent studies elucidated several possible reasons, including the activation of other inhibitory immune cells, low immune cell infiltration in the tumor microenvironment, different immune properties of OS subtypes, and the involvement of osteogenesis and osteolysis. According to these mechanisms, researchers have developed new methods to overcome the shortcomings of ICIs. This review summarizes the recent breakthroughs in the use of ICIs to treat OS. Although numerous issues have not been solved yet, ICIs are still the most promising treatment options to cure OS in the long run.<\/jats:p>","DOI":"10.3389\/fphar.2022.1031527","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T06:11:52Z","timestamp":1665987112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future"],"prefix":"10.3389","volume":"13","author":[{"given":"Zeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengfeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ocl.2015.08.022","article-title":"Update on survival in osteosarcoma","volume":"47","author":"Anderson","year":"2016","journal-title":"Orthop. Clin. North Am."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: Beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1186\/s12885-022-09697-9","article-title":"Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and\/or recurrent osteosarcoma (EuroSarc-Memos trial)","volume":"22","author":"Barnes","year":"2022","journal-title":"BMC Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/0008-5472.can-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.3390\/cancers14112694","article-title":"Surgical treatment of bone sarcoma","volume":"14","author":"Bl\u00e4sius","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s00262-021-02876-w","article-title":"Pembrolizumab in advanced osteosarcoma: Results of a single-arm, open-label, phase 2 trial","volume":"70","author":"Boye","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily-CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/scrt34","article-title":"New concepts on the immune modulation mediated by mesenchymal stem cells","volume":"1","author":"Bunnell","year":"2010","journal-title":"Stem Cell Res. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1667\/rade-20-00017","article-title":"The effect of concurrent stereotactic body radiation and anti-PD-1 therapy for recurrent metastatic sarcoma","volume":"194","author":"Callaghan","year":"2020","journal-title":"Radiat. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000369975","article-title":"RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: A possible step forward?","volume":"88","author":"Cathomas","year":"2015","journal-title":"Oncology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.omto.2021.07.014","article-title":"Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma","volume":"22","author":"Christie","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/s1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo","year":"2018","journal-title":"Lancet. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"996","DOI":"10.4049\/jimmunol.175.2.996","article-title":"Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation","volume":"175","author":"Darlington","year":"2005","journal-title":"J. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): A multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/cas.14398","article-title":"Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma","volume":"111","author":"Deng","year":"2020","journal-title":"Cancer Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1002\/cam4.1518","article-title":"Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases","volume":"7","author":"Dhupkar","year":"2018","journal-title":"Cancer Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-022-01876-6","article-title":"Toll-like receptor 9 agonists and combination therapies: Strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity","author":"Dongye","year":"2022","journal-title":"Br. J. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-030-35723-8_8","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment","volume":"1224","author":"Dysthe","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/ni1003","article-title":"Modulation of tryptophan catabolism by regulatory T cells","volume":"4","author":"Fallarino","year":"2003","journal-title":"Nat. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.imlet.2010.09.022","article-title":"New monoclonal antibodies against B-cell antigens: Possible new strategies for diagnosis of primary cutaneous B-cell lymphomas","volume":"134","author":"Fanoni","year":"2011","journal-title":"Immunol. Lett."},{"key":"B23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5301\/tj.5000696","article-title":"EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.","volume":"104","author":"Ferrari","year":"2018","journal-title":"Tumori"},{"key":"B24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/(SICI)1521-4141(199903)29:03<838::AID-IMMU838>3.0.CO;2-P","article-title":"CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells","volume":"29","author":"Fraser","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/s1074-7613(02)00323-0","article-title":"The CD28 signaling pathway regulates glucose metabolism","volume":"16","author":"Frauwirth","year":"2002","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1089\/dna.2017.3669","article-title":"Evidence of interleukin 21 reduction in osteosarcoma patients due to PD-1\/PD-L1-mediated suppression of follicular helper T cell functionality","volume":"36","author":"Gao","year":"2017","journal-title":"DNA Cell Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s1470-2045(19)30693-x","article-title":"Atezolizumab for children and young adults with previously treated solid tumours, non-hodgkin lymphoma, and hodgkin lymphoma (iMATRIX): A multicentre phase 1-2 study","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbo.2017.10.002","article-title":"Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer","volume":"9","author":"Guan","year":"2017","journal-title":"J. Bone Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1007\/s00268-016-3500-7","article-title":"Amputation versus limb-salvage surgery in patients with osteosarcoma: A meta-analysis","volume":"40","author":"Han","year":"2016","journal-title":"World J. Surg."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.3390\/cancers14143331","article-title":"The role of metabolic plasticity of tumor-associated macrophages in shaping the tumor microenvironment immunity","volume":"14","author":"Hasan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"E528","DOI":"10.3390\/diagnostics10080528","article-title":"Characterization of PD-1\/PD-L1 immune checkpoint expression in osteosarcoma","volume":"10","author":"Hashimoto","year":"2020","journal-title":"Diagn. (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ijrobp.2020.09.041","article-title":"Reduction of lung metastases in a mouse osteosarcoma model treated with carbon ions and immune checkpoint inhibitors","volume":"109","author":"Helm","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejca.2019.07.029","article-title":"The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma","volume":"125","author":"Heng","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e003633","DOI":"10.1136\/jitc-2021-003633","article-title":"Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors","volume":"10","author":"Hu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.7150\/jca.25011","article-title":"Prognostic value of programmed cell death 1 ligand-1 (PD-L1) or PD-1 expression in patients with osteosarcoma: A meta-analysis","volume":"9","author":"Huang","year":"2018","journal-title":"J. Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy","volume":"94","author":"Intlekofer","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"Embo J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"105818","DOI":"10.1016\/j.intimp.2019.105818","article-title":"SDF-1\/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy","volume":"75","author":"Jiang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/s1470-2045(14)70412-7","article-title":"Carbon ion radiotherapy in Japan: An assessment of 20 years of clinical experience","volume":"16","author":"Kamada","year":"2015","journal-title":"Lancet. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0271205","DOI":"10.1371\/journal.pone.0271205","article-title":"Radiation therapy enhances systemic antitumor efficacy in PD-L1 therapy regardless of sequence of radiation in murine osteosarcoma","volume":"17","author":"Katsuki","year":"2022","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J. Exp. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejphar.2014.10.048","article-title":"Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and\/or G1 arrest in tumor cells","volume":"746","author":"Kimura","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"30093","DOI":"10.1038\/srep30093","article-title":"Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma","volume":"6","author":"Koirala","year":"2016","journal-title":"Sci. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00262-015-1731-3","article-title":"A phase I trial combining decitabine\/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma","volume":"64","author":"Krishnadas","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejca.2019.07.018","article-title":"Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: Results from the PEMBROSARC study","volume":"119","author":"Le Cesne","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1002\/eji.200324228","article-title":"Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses","volume":"33","author":"Liang","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e001772","DOI":"10.1136\/jitc-2020-001772","article-title":"Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes","volume":"9","author":"Ligon","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.4049\/jimmunol.1401282","article-title":"IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells","volume":"193","author":"Lim","year":"2014","journal-title":"J. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1073\/pnas.0712278105","article-title":"The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors","volume":"105","author":"Lin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B55","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.4049\/jimmunol.151.7.3489","article-title":"Characterization of CTLA-4 structure and expression on human T cells","volume":"151","author":"Lindsten","year":"1993","journal-title":"J. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.Cir-15-0230","article-title":"Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"830546","DOI":"10.3389\/fonc.2022.830546","article-title":"Novel immunotherapies for osteosarcoma","volume":"12","author":"Lu","year":"2022","journal-title":"Front. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/s0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): A randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40425-015-0067-z","article-title":"Combination immunotherapy with \u03b1-CTLA-4 and \u03b1-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma","volume":"3","author":"Lussier","year":"","journal-title":"J. Immunother. Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/cji.0000000000000065","article-title":"Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1\/PD-L1 interactions","volume":"38","author":"Lussier","year":"","journal-title":"J. Immunother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"117925","DOI":"10.1016\/j.lfs.2020.117925","article-title":"Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt\/\u03b2-catenin pathway","volume":"256","author":"Lv","year":"2020","journal-title":"Life Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nature05478","article-title":"Foxp3 occupancy and regulation of key target genes during T-cell stimulation","volume":"445","author":"Marson","year":"2007","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","first-page":"250","DOI":"10.17179\/excli2021-4094","article-title":"Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma","volume":"21","author":"Meftahpour","year":"2022","journal-title":"Excli J."},{"key":"B64","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/1078-0432.Ccr-15-0491","article-title":"Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e27944","DOI":"10.1371\/journal.pone.0027944","article-title":"Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer","volume":"6","author":"Michielsen","year":"2011","journal-title":"PLoS One"},{"key":"B67","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.immuni.2014.04.016","article-title":"Development and function of dendritic cell subsets","volume":"40","author":"Mildner","year":"2014","journal-title":"Immunity"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00262-020-02774-7","article-title":"Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma","volume":"70","author":"Mochizuki","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"B69","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nri3073","article-title":"Protective and pathogenic functions of macrophage subsets","volume":"11","author":"Murray","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fonc.2013.00049","article-title":"Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer","volume":"3","author":"Najjar","year":"2013","journal-title":"Front. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.3390\/cancers13112696","article-title":"Overcoming PD-1 inhibitor resistance with a monoclonal antibody to secreted frizzled-related protein 2 in metastatic osteosarcoma","volume":"13","author":"Nasarre","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B73","doi-asserted-by":"publisher","first-page":"577766","DOI":"10.3389\/fimmu.2021.577766","article-title":"Sunitinib exerts in vitro immunomodulatory activity on sarcomas via dendritic cells and synergizes with PD-1 blockade","volume":"12","author":"Ocadlikova","year":"2021","journal-title":"Front. Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.290.5492.816","article-title":"Structure of murine CTLA-4 and its role in modulating T cell responsiveness","volume":"290","author":"Ostrov","year":"2000","journal-title":"Science"},{"key":"B76","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/mcb.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J. Exp. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/jrr\/rrab050","article-title":"High linear energy transfer carbon-ion irradiation upregulates PD-L1 expression more significantly than X-rays in human osteosarcoma U2OS cells","volume":"62","author":"Permata","year":"2021","journal-title":"J. Radiat. Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/s1470-2045(16)30096-1","article-title":"Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): A randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Piperno-Neumann","year":"2016","journal-title":"Lancet. Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"B81","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.prro.2014.08.015","article-title":"Clinical outcomes of palliative radiation therapy for children","volume":"5","author":"Rahn","year":"2015","journal-title":"Pract. Radiat. Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/cgt.2011.83","article-title":"Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma","volume":"19","author":"Rainusso","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41419-019-1497-1","article-title":"Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways","volume":"10","author":"Ren","year":"2019","journal-title":"Cell Death Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fonc.2018.00004","article-title":"Osteosarcoma: Accelerating progress makes for a hopeful future","volume":"8","author":"Saraf","year":"2018","journal-title":"Front. Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1126\/science.1131078","article-title":"Reversal of the TCR stop signal by CTLA-4","volume":"313","author":"Schneider","year":"2006","journal-title":"Science"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/cncr.30411","article-title":"Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American group of osteosarcoma treatment","volume":"123","author":"Senerchia","year":"2017","journal-title":"Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri3070","article-title":"Monocyte recruitment during infection and inflammation","volume":"11","author":"Shi","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"100206","DOI":"10.1016\/j.jbo.2018.11.001","article-title":"Specific inhibition of PI3K\u03b4\/\u03b3 enhances the efficacy of anti-PD1 against osteosarcoma cancer","volume":"16","author":"Shi","year":"2019","journal-title":"J. Bone Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1084\/jem.20050072","article-title":"In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses","volume":"201","author":"Shin","year":"2005","journal-title":"J. Exp. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"Ca. Cancer J. Clin."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e001458","DOI":"10.1136\/jitc-2020-001458","article-title":"Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients","volume":"9","author":"Starzer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/s1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet. Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1158\/0008-5472.Can-11-0993","article-title":"IL-18 induces PD-1-dependent immunosuppression in cancer","volume":"71","author":"Terme","year":"2011","journal-title":"Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"E1594","DOI":"10.1073\/pnas.1503286112","article-title":"Combinatorial proteomic analysis of intercellular signaling applied to the CD28 T-cell costimulatory receptor","volume":"112","author":"Tian","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B96","doi-asserted-by":"publisher","first-page":"e27763","DOI":"10.1002\/pbc.27763","article-title":"Curative-intent radiotherapy for pediatric osteosarcoma: The St. Jude experience","volume":"66","author":"Tinkle","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1349-7006.2008.00695.x","article-title":"Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma","volume":"99","author":"Tsukahara","year":"2008","journal-title":"Cancer Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.intimp.2016.05.016","article-title":"The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma","volume":"38","author":"Wang","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3389\/fimmu.2019.01114","article-title":"Innate immune cells: A potential and promising cell population for treating osteosarcoma","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"840029","DOI":"10.3389\/fimmu.2022.840029","article-title":"Metabolic reprogramming induces macrophage polarization in the tumor microenvironment","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","article-title":"Immuno-genomic landscape of osteosarcoma","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"key":"B103","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jbo.2018.05.002","article-title":"Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma","volume":"12","author":"Xia","year":"2018","journal-title":"J. Bone Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e000798","DOI":"10.1136\/jitc-2020-000798","article-title":"Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: A single-arm, open-label, phase 2 trial","volume":"8","author":"Xie","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.2147\/ott.S198421","article-title":"Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers","volume":"12","author":"Yoshida","year":"2019","journal-title":"Onco. Targets. Ther."},{"key":"B106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12885-019-6499-y","article-title":"Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells","volume":"20","author":"Yoshida","year":"2020","journal-title":"BMC Cancer"},{"key":"B107","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"key":"B108","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s1074-7613(04)00051-2","article-title":"Structural and functional analysis of the costimulatory receptor programmed death-1","volume":"20","author":"Zhang","year":"2004","journal-title":"Immunity"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3892\/or.2019.7299","article-title":"PD-L1\/PD-1 axis serves an important role in natural killer cell-induced cytotoxicity in osteosarcoma","volume":"42","author":"Zhang","year":"2019","journal-title":"Oncol. Rep."},{"key":"B110","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s10120-021-01159-8","article-title":"Apatinib induced ferroptosis by lipid peroxidation in gastric cancer","volume":"24","author":"Zhao","year":"2021","journal-title":"Gastric Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"9854904","DOI":"10.34133\/2022\/9854904","article-title":"lncRNA HITT inhibits lactate production by repressing PKM2 oligomerization to reduce tumor growth and macrophage polarization","volume":"2022","author":"Zhao","year":"2022","journal-title":"Res. (Wash D C)"},{"key":"B112","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/apm.12311","article-title":"Expression of programmed death 1 is correlated with progression of osteosarcoma","volume":"123","author":"Zheng","year":"2015","journal-title":"Apmis"},{"key":"B113","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-018-0560-1","article-title":"PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse","volume":"11","author":"Zheng","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1158\/2326-6066.Cir-16-0259","article-title":"All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2057892","DOI":"10.1080\/2162402x.2022.2057892","article-title":"Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice","volume":"11","author":"Zhou","year":"2022","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1031527\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T15:12:17Z","timestamp":1678288337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1031527\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":115,"alternative-id":["10.3389\/fphar.2022.1031527"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1031527","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"article-number":"1031527"}}